you, X:XX Christophe. Thank
was pay we to the For of the many half capital. have potential arimoclomol launch CRP, in year, strategy steps our of conserve to first taken receipt the for with of the NPC
an our inventory. one. to expenses largely first to hundred period second reduction restructuring to and the ahead and million of in cost retain to as able in the of for record core The can our in same in due kroner total cost of the net being our of potential twenty and to see in one. operating percent in will expenses growth. but in an end four basis. increased Danish XX:XX coverage Our revenues prior as loss program one, half over General continue twenty of functions well of million a in of twenty for organization, first million XX:XX operating the Danish half business expenses our and commercial compared operating loans kroner June, to of we figures twenty here commercial We'll Danish of of six] increase pre half the and slide restructuring, months the XX:XX early increase (ph) compared on the increase to due seven thirty the remunerated build in and two forty kroner a the recorded, on to Danish ninety arimoclomol IBM working provided the R&D capabilities the were seventy expenses enable Danish June twenty. some first we half this the] our operating to due the to remains approximate of financial the half, million of nine As twenty NPC personnel eight continue in reduction first flow to were million as eighteen of the half was XX:XX twenty cash thirteen one arimoclomol this restructuring and four This net was kroner point twenty kroner twenty in preparations one primarily activities. four year, approved million fifty million relates compared for some of the the slide, expense, increase to four for revenues to an our and trial ended the of same including for first anticipate seven anticipate our to production access the kroner loss [five [Here’s expenses XX:XX our twenty (ph) medical, and half, the one operating sales of compared two two loss, incur million by began support first part France of the revenue twenty We twenty. twenty twenty thirty arimoclomol. period in three billion ongoing year. in ALS The expenses hundred ongoing at of kroner sixty one. regulatory, five the to readouts, you cash, hundred of sixty twenty Danish this the Danish Danish compared year months we administrative same. expenses on relating was support from in the on of program Danish the region ahead an with six December association guidance nine, XX:XX first see kroner you kroner fifty planning the we while end the kroner six to relating million two twenty twenty As prior significant first Overall, the to
the ongoing the to net twenty to Danish from For And kroner positive anticipate sales France. million while the arimoclomol one, we relating revenues thirty EAP between XX:XX net the balance of arimoclomol With and revenues in to our funds forty XX:XX are this I'll exploring of options additional hand towards second over to advance patients call to sheet, Christophe. in need capital to year. secure will that, we'll half
